Does Mechanical Circulatory Support-Assisted Percutaneous Coronary Intervention Improve Left Ventricular Function?
作者信息
Fahed Akl C, Jaffer Farouc A
机构信息
Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Cardiovascular Disease Initiative, Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts.
出版信息
J Soc Cardiovasc Angiogr Interv. 2022 Aug 13;1(5):100387. doi: 10.1016/j.jscai.2022.100387. eCollection 2022 Sep-Oct.
Abstract
摘要
相似文献
1
Does Mechanical Circulatory Support-Assisted Percutaneous Coronary Intervention Improve Left Ventricular Function?
J Soc Cardiovasc Angiogr Interv. 2022 Aug 13;1(5):100387. doi: 10.1016/j.jscai.2022.100387. eCollection 2022 Sep-Oct.
2
Improvement in left ventricular function following higher-risk percutaneous coronary intervention in patients with ischemic cardiomyopathy.
Catheter Cardiovasc Interv. 2020 Oct 1;96(4):764-770. doi: 10.1002/ccd.28557. Epub 2019 Nov 6.
3
[Effects of percutaneous coronary intervention on cardiac function in ischemic cardiomyopathy patients with different left ventricular ejection fraction and SYNTAX score≤22].
Zhonghua Yi Xue Za Zhi. 2020 Sep 22;100(35):2768-2773. doi: 10.3760/cma.j.cn112137-20200116-00106.
4
Impact of Impella protected-percutaneous coronary intervention on left ventricle function recovery of patients with extensive coronary disease and poor left ventricular function.
Int J Cardiol. 2023 Sep 15;387:131098. doi: 10.1016/j.ijcard.2023.05.048. Epub 2023 Jun 7.
5
Catheter ablation of hemodynamically unstable ventricular tachycardia with mechanical circulatory support.
Int J Cardiol. 2013 Oct 9;168(4):3859-65. doi: 10.1016/j.ijcard.2013.06.035. Epub 2013 Jul 15.
6
Effectiveness of a percutaneous left ventricular assist device in preventing acute hemodynamic decompensation during catheter ablation of ventricular tachycardia in advanced heart failure patients: A retrospective single-center analysis.
J Cardiovasc Electrophysiol. 2019 Dec;30(12):2864-2868. doi: 10.1111/jce.14199. Epub 2019 Oct 2.
7
Left brachial artery: one more way to percutaneous insertion of IMPELLA 2.5L circulatory support for high-risk percutaneous coronary intervention - a case report.
Eur Heart J Case Rep. 2020 Oct 21;4(6):1-5. doi: 10.1093/ehjcr/ytaa281. eCollection 2020 Dec.
8
Coronary artery bypass grafting under sole Impella 5.0 support for patients with severely depressed left ventricular function.
J Artif Organs. 2022 Jun;25(2):158-162. doi: 10.1007/s10047-021-01285-1. Epub 2021 Jun 24.
9
Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy.
Eur Heart J Acute Cardiovasc Care. 2020 Mar;9(2):173-182. doi: 10.1177/2048872618777876. Epub 2018 May 24.
10
Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study.
J Cardiovasc Med (Hagerstown). 2008 Oct;9(10):1004-10. doi: 10.2459/JCM.0b013e3282f9abe7.
本文引用的文献
1
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1.
2
Variability in Coronary Artery Disease Testing for Patients With New-Onset Heart Failure.
J Am Coll Cardiol. 2022 Mar 8;79(9):849-860. doi: 10.1016/j.jacc.2021.11.061.
3
The Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease (OPTIMUM) Registry: Rationale and Design.
Cardiovasc Revasc Med. 2022 Aug;41:83-91. doi: 10.1016/j.carrev.2022.01.008. Epub 2022 Jan 31.
4
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation. 2022 Jan 18;145(3):e18-e114. doi: 10.1161/CIR.0000000000001038. Epub 2021 Dec 9.
5
Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial.
Circulation. 2020 Nov 3;142(18):1725-1735. doi: 10.1161/CIRCULATIONAHA.120.050304. Epub 2020 Aug 29.
6
Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry.
J Interv Cardiol. 2019 Apr 9;2019:5243913. doi: 10.1155/2019/5243913. eCollection 2019.
7
Improvement in left ventricular function following higher-risk percutaneous coronary intervention in patients with ischemic cardiomyopathy.
Catheter Cardiovasc Interv. 2020 Oct 1;96(4):764-770. doi: 10.1002/ccd.28557. Epub 2019 Nov 6.
8
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy.
N Engl J Med. 2019 Aug 22;381(8):739-748. doi: 10.1056/NEJMoa1807365.
9
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.
Eur Heart J. 2017 Nov 7;38(42):3124-3134. doi: 10.1093/eurheartj/ehx512.
10
Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention.
Circulation. 2014 Dec 23;130(25):2295-301. doi: 10.1161/CIRCULATIONAHA.114.011541. Epub 2014 Nov 12.
Zotero 插件